

Clinical Policy: Fluticasone Propionate (Xhance)

Reference Number: CP.PMN.95

Effective Date: 10.24.17

Last Review Date: 02.18

Line of Business: Commercial*, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Fluticasone propionate (Xhance[™]) is a synthetic trifluorinated corticosteroid with anti-inflammatory activity with a unique nasal delivery device.

**For Commercial Exchange Plans, this policy applies only when the prescribed agent is on the formulary. Request for non-formulary agent must be reviewed using the formulary exception policy.*

FDA Approved Indication(s)

Xhance is indicated for the treatment of nasal polyps in patients 18 years of age or older.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Xhance is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Nasal Polyps (must meet all):

1. Diagnosis of nasal polyps;
2. Age \geq 18 years;
3. Failure of a trial of two formulary intranasal steroids (e.g., fluticasone propionate, mometasone, budesonide) unless all are contraindicated or clinically significant adverse effects are experienced;
4. Dose does not exceed 744 mcg/day (2 devices per 30 days).

Approval duration:

Medicaid – 12 months

Commercial – Length of benefit

B. Other diagnoses/indications

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. Nasal Polyps (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;

CLINICAL POLICY

Fluticasone Propionate

2. Member is responding positively to therapy (e.g., improvement in nasal congestion or obstruction, reduction of bilateral polyp grade);
3. If request is for a dose increase, new dose does not exceed 744 mcg/day (2 devices per 30 days).

Approval duration:

Medicaid – 12 months

Commercial – Length of benefit

B. Other diagnoses/indications(must meet 1 or 2):

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

Approval duration: Duration of request or 12 months (whichever is less); or

2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – CP.CPA.09 for commercial and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug	Dosing Regimen	Dose Limit/ Maximum Dose
mometasone furoate (Nasonex [®])	2 sprays/nostril (50 mcg/spray) IN BID (400 mcg/day)	400 mcg/day
fluticasone propionate (Flonase [®])	2-4 sprays/nostril (50 mcg/spray) IN QD or BID (200 - 800 mcg)	800 mcg/day
budesonide (Rhinocort [®])	2 sprays/nostril (32 mcg/spray) IN QD (128 mcg)	128 mcg/day

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
------------	----------------	--------------

CLINICAL POLICY

Fluticasone Propionate

Nasal polyps	1 spray per nostril (93 mcg/spray) IN BID; 2 sprays per nostril IN BID may also be effective in some patients.	744 mcg/day
--------------	---	-------------

VI. Product Availability

Nasal spray: 93 mcg of fluticasone propionate in each 106-mg spray with 120 metered sprays per device

VII. References

1. Optinose[®]. Optinose[®] announces FDA approval of Xhance nasal spray for the treatment of nasal polyps. September 2017; Available at <http://www.optinose.com/press-releases/optinose-announces-fda-approval-xhance-fluticasone-propionate-nasal-spray-treatment-nasal-polyps>. Accessed October 9, 2017.
2. Xhance Prescribing Information. Yardley, PA; Optinose[®]: September 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209022s000lbl.pdf. Accessed October 9, 2017.
3. Newton JR, Ah-see KW. A review of nasal polyposis. Ther Clin Risk Manag. 2008;4(2):507-12. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504067/>. Accessed October 9, 2017
4. Sotores D., Messina J., Carothers J., et al. A randomized, double-blind of an Exhalation Delivery System with fluticasone (EDS-FLU) for treatment of chronic rhinosinusitis with nasal polys (CRSwNP) (NAVIGATE I). Journal of Allergy and Clinical Immunology , Volume 139 , Issue 2 , AB66. Feb 2017 Available at: http://www.optinose.com/wp-content/uploads/2017/10/AAAI_NAVIGATE_I_EDS-FLU_CRSwNP.pdf. Accessed October 9, 2017
5. Leopold D., Elkayam D., Messina J. et al. A randomized double-blind trial of fluticasone propionate exhalation delivery system (FLU-EDS) for treatment of chronic rhinosinusitis with nasal polyps (NAVIGATE II). The University of Vermont, Optinose. 2017 Available at: http://www.optinose.com/wp-content/uploads/2017/10/NAVIGATE_II_FLU-EDS_for_CRSwNP.pdf. Accessed October 9, 2017
6. Nasonex Prescribing Information. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; March 2013. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020762s038lbl.pdf. Accessed October 13, 2017
7. Filiaci F, Passali D, Puxeddu R, Schrewelius C. A randomized controlled trial showing efficacy of once daily intranasal budesonide in nasal polyposis. Rhinology. 2000 Dec;38(4):185-90. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11190754>. Accessed October 13, 2017
8. Jankowski R, Klossek JM, Attali V, Coste A, Serrano E. Long-term study of fluticasone propionate aqueous nasal spray in acute and maintenance therapy of nasal polyposis. Allergy. 2009 Jun;64(6):944-50. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19298572>. Accessed October 13, 2017

Reviews, Revisions, and Approvals	Date	P&T Approval Date
-----------------------------------	------	-------------------

CLINICAL POLICY
Fluticasone Propionate

Policy created	10.24.17	02.18
----------------	----------	-------

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed

CLINICAL POLICY

Fluticasone Propionate

herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.